Head to Head Survey: ReShape Lifesciences (OTCMKTS:RSLSD) vs. Edap Tms (OTCMKTS:EDAP)

ReShape Lifesciences (OTCMKTS:RSLSD) and Edap Tms (NASDAQ:EDAP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.

Institutional & Insider Ownership

12.0% of Edap Tms shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

ReShape Lifesciences has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Comparatively, Edap Tms has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for ReShape Lifesciences and Edap Tms, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ReShape Lifesciences 0 0 0 0 N/A
Edap Tms 0 0 1 0 3.00

Edap Tms has a consensus target price of $6.50, suggesting a potential upside of 23.57%. Given Edap Tms’ higher probable upside, analysts plainly believe Edap Tms is more favorable than ReShape Lifesciences.

Profitability

This table compares ReShape Lifesciences and Edap Tms’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ReShape Lifesciences -668.58% -163.22% -52.10%
Edap Tms 7.61% 40.29% 20.63%

Valuation and Earnings

This table compares ReShape Lifesciences and Edap Tms’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ReShape Lifesciences $610,000.00 3.12 -$81.15 million N/A N/A
Edap Tms $46.17 million 3.30 -$400,000.00 $0.02 263.00

Edap Tms has higher revenue and earnings than ReShape Lifesciences.

Summary

Edap Tms beats ReShape Lifesciences on 9 of the 10 factors compared between the two stocks.

ReShape Lifesciences Company Profile

ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.

Edap Tms Company Profile

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS). The HIFU division develops, manufactures, and markets devices for the minimally invasive destruction of various types of localized tumors using HIFU technology. It offers Ablatherm, a HIFU device for the treatment of organ-confined prostate cancer, referred to as T1-T2 stage; and Focal One device, a HIFU robotic device for the focal therapy of localized prostate cancer. This division also leases equipment; sells consumables; and offers treatment related services and maintenance services. The UDS division develops, manufactures, markets, and services medical devices for the minimally invasive diagnosis or treatment of urological disorders, primarily urinary stones and other clinical indications. It offers lithotripters, such as Sonolith i-move and Sonolith i-sys for the treatment of urinary tract stones by means of extracorporeal shockwave lithotripsy technology. This division also leases lithotripters; sells disposables and spare parts; and provides maintenance services. The company markets and sells its products through its direct marketing and sales organization, as well as through third-party distributors and agents. Its customers include public and private hospitals, urology clinics, and research institutions. The company was founded in 1979 and is headquartered in Vaulx-en-Velin, France.

Receive News & Ratings for ReShape Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReShape Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.